Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Vomiting 6Nausea 3Neoplasms 2Uterine Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1Melanoma 1Gynecologic Cancer 1Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pralsetinib 2pembrolizumab 2Brentuximab Vedotin 2Bevacizumab 2ribociclib 1fosaprepitant 1Sunitinib 1Sirolimus 1Radiotherapy, Image-Guided 1Plicamycin 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Genistein 1Gemcitabine 1Erlotinib Hydrochloride 1Dexamethasone 1Cisplatin 1Carboplatin 1Aprepitant 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Germ Cell and Embryonal × fosaprepitant × Clear all
NCT01736917 2016-05-25

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

Hoosier Cancer Research Network

Phase 2 Completed
65 enrolled 14 charts
Genitourinary

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡